| 000 | 01620 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250517234215.0 | ||
| 264 | 0 | _c20200728 | |
| 008 | 202007s 0 0 eng d | ||
| 022 | _a2160-7648 | ||
| 024 | 7 |
_a10.1002/cpdd.611 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOthman, Ahmed A | |
| 245 | 0 | 0 |
_aPharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis. _h[electronic resource] |
| 260 |
_bClinical pharmacology in drug development _c05 2019 |
||
| 300 |
_a492-502 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aInterleukin-17 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aKhatri, Amit | |
| 700 | 1 | _aLoebbert, Ralf | |
| 700 | 1 | _aPeloso, Paul M | |
| 773 | 0 |
_tClinical pharmacology in drug development _gvol. 8 _gno. 4 _gp. 492-502 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cpdd.611 _zAvailable from publisher's website |
| 999 |
_c28777961 _d28777961 |
||